A Rare Case of Prototheca Algaemia in a Patient with Systemic Lupus Erythematosus and Recent Belimumab Infusion

Carolina Mejia-Otero,1 Shelley Singh,1 Luis Arias Urdaneta,2 Carlos Sesin,2 Anindita Chakrabarti,3 Nanci Mae Miller,4 and Claudio Tuda5

1 Internal Medicine Department, Mount Sinai Medical Center, Miami, FL 33140, USA
2 Division of Rheumatology, Internal Medicine Department, Mount Sinai Medical Center, Miami, FL, USA
3 Department of Infectious Disease, University of Miami Miller School of Medicine, Miami, FL 33136, USA
4 Department of Pathology, Mount Sinai Medical Center, Miami, FL, USA
5 Division of Infectious Disease, Internal Medicine Department, Mount Sinai Medical Center, Miami, FL, USA

Correspondence should be addressed to Carolina Mejia-Otero, caroliname85@gmail.com

Received 29 August 2012; Accepted 23 October 2012

A better understanding of the pathogenesis of immune-mediated diseases has led to the development of a new therapeutic approach to SLE, B-cell-targeted therapy. This acts through two principal mechanisms: direct killing by monoclonal antibodies specific for B-cell surface molecules CD19, CD20 (rituximab, ocrelizumab), and CD22 (epratuzumab) and attrition due to the inhibition of B-cell survival factors BLyS (belimumab) and APRIL (atacicept) [4]. Belimumab is the first targeted biological treatment that is FDA approved specifically for the treatment of SLE [5]. Previous randomized controlled trials have shown reductions in disease activity and prevention of flares [6, 7], with an acceptable safety profile [8]; however, malignancies, serious or severe infections, and infusion reactions have been described [4, 5].

1. Introduction

SLE is a heterogeneous disease caused by an aberrant autoimmune response that spares no organ and affects people of African, Hispanic, and Asian ancestry more than other racial or ethnic groups [1, 2]. Genetic, environmental, hormonal, and immunoregulatory factors contribute to the expression of tissue injury and clinical manifestations. Both T and B cell antigen receptor-mediated activation are altered and early signaling events are amplified [1, 3]. All B-cell subgroups contribute to the production of autoantibodies. These play an important role in the presentation of antigens and auto-antigens to T cells, thus mediating tissue damage and contributing to disease expression [1].
2. Case Presentation

We describe a case of a 67-year-old female with SLE on immunosuppressive therapy for more than five years who presented to the hospital with a two-day history of cough, fever, and fatigue. One week prior to admission, she received her third belimumab infusion (10 mg/kg) without acute complications. Her first two loading doses of belimumab were four and two weeks earlier, again, without incident. The patient was diagnosed with SLE over five years ago, based upon a history of immune thrombocytopenia and autoimmune hemolytic anemia (Evan’s syndrome), hypocomplementemia, polyarthralgias, and a positive ANA in a 1:160 speckled pattern. She had multiple flares of hemolytic anemia requiring high doses of steroids as well as several immunosuppressive therapies. Her regimen at the time of her admission consisted of azathioprine 50 mg twice daily and prednisone 60 mg daily. Her comorbidities included DM, essential hypertension, drug-induced osteoporosis, and cataracts, as well as a history of a left middle cerebral artery aneurysm status after clipping. Other medications were long-acting insulin, tramadol, lisinopril, metoprolol, and folic acid.

At admission, the patient was tachycardic with a low-grade fever and hypoxemia. Physical examination revealed coarse breath sounds bilaterally. Laboratory data and imaging showed leukocytosis and bilateral infiltrates consistent with multifocal pneumonia. IV antibiotics were initiated; however, the patient subsequently developed respiratory failure leading to multiple intubations throughout her hospital course and eventual tracheostomy. Results of bronchoalveolar lavages revealed *Pneumocystis jiroveci*, *Cytomegalovirus*, and *Herpes simplex virus*; blood cultures grew *E. faecalis* and *K. pneumoniae* (see Table 1). Multiple antimicrobials were employed to treat the numerous infections, including clindamycin, gancyclovir, linezolid, ceftaroline, ampicillin, valacyclovir, and trimethoprim-sulfa. The patient had persistent fevers despite multiple antimicrobial therapies and subsequent blood cultures yielded the growth of *P. wickerhamii* (Figures 1 and 2), which was treated with amphotericin B for two weeks. Repeat blood cultures remained negative after treatment.

3. Discussion

Human protothecosis is a rare infection caused by members of the genus *Prototheca*, a microscopic single-celled heterotrophic, chlorophyllic algae that belongs to the family Chlorellaceae. It reproduces by endosporulation and binary...
fission and is ubiquitous in nature; the most common species causing infection in humans is *P. wickerhamii* [9–11]. The appearance of *Prototheca* is similar to yeast on routine media but may be distinguished from yeast on wet mounts with lactophenol cotton blue staining if typical morula forms are observed [12].

Patients at risk for developing protothecosis are those with chronic steroid use, hematological or solid tissue malignancy, or other immunocompromised states such as DM, autoimmune disease, or primary immunodeficiency; however, cases in immunocompetent patients have also been described [13]. In the immunosuppressed individual, opportunistic infection with *Prototheca* species may be associated with bacterial, viral, or fungal coinfection, complicating both diagnosis and treatment [12].

Cellular immunity and polymorphonuclear leukocytes (PMNs), along with IgG antibodies and serum opsonins, are involved in the host defense against *Prototheca* spp. Optimal phagocytosis and killing of *P. wickerhamii* by PMNs require the presence of both specific IgG antibody and heat-labile opsonins observed after ultrastructural studies [14].

To date, there are 160 reported cases of human protothecosis, six (4%) of which have documented algæaemia [13]. Most *Prototheca* infections occur on the skin or bursae; blood infections are rare and are highly associated with an immunocompromised state, such as that which occurred with this patient with SLE, DM, and on immunosuppressive therapy. Nonetheless, only after receiving belimumab did she develop protothecosis. We propose that belimumab may have contributed to the development of this *Prototheca* infection, as her longstanding immunosuppressed state had not led her to this rare opportunistic infection in the past.

One case report of protothecosis in a hematopoietic stem cell transplant recipient has been described after infliximab treatment, another biologic agent that can lead to immunosuppression [9, 15]. No cases of human protothecosis in patients receiving belimumab have been described in the literature thus far, but the correlation does not necessarily mean causation in our patient since she was on corticosteroids and azathioprine prior to the first dose of belimumab. Nevertheless, this paper illustrates that unusual infections have to be considered in all patients undergoing immunosuppressive therapy who persist with fever despite conventional antibiotic, antiviral, and antifungal treatments. Further studies or observation of uncommon adverse events in patients with belimumab are needed.

### Conflict of Interests

The authors declare that they have no conflict of interests.

### Acknowledgments

The authors gratefully acknowledge the assistance of Francisco Yuri Bulcao de Macedo, MD, from Jackson Memorial Hospital, Miami, FL, USA, and Alicia Hirzel, MD, from the Department of Pathology at Mount Sinai Medical Center.

### References

[1] G. Tsokos, “Mechanism of disease: systemic lupus erythematosus,” *The New England Journal of Medicine*, vol. 365, pp. 2110–2121, 2011.

[2] C. Duarte, M. Couto, L. Ines, and M. H. Liang, “Epidemiology of systemic lupus erythematosus,” in *Systemic Lupus Erythematosus*, R. G. Lahita, G. Tsokos, I. Buyon, and T. Kioke, Eds., pp. 673–696, Elsevier, London, UK, 5th edition, 2011.

[3] J. C. Crispin, S. N. C. Liossis, K. Kis-Toth et al., “Pathogenesis of human systemic lupus erythematosus: recent advances,” *Trends in Molecular Medicine*, vol. 16, no. 2, pp. 47–57, 2010.

[4] M. Ramos-Casals, I. Sanz, X. Bosch, J. Stone, and M. Khamashta, “B-cell-depleting therapy in systemic lupus erythematosus,” *The American Journal of Medicine*, vol. 125, pp. 327–336, 2012.

[5] S. V. Navarra, R. M. Guzmán, A. E. Gallacher et al., “Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial,” *The Lancet*, vol. 377, no. 9767, pp. 721–731, 2011.

[6] W. Stohl, F. Hiepe, K. Latinis et al., “Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus,” *Arthritis & Rheumatism*, vol. 64, no. 7, pp. 2328–2337, 2012.

[7] D. "Cruz, S. Manzi, J. Sánchez-Guerrero et al., “Belimumab reduced disease activity across multiple organ domains in patients with SLE: combined results from BLISS-52 and BLISS-76,” *Annals of the Rheumatic Diseases*, vol. 71, no. 11, pp. 1833–1838, 2012.

[8] J. Merrill, E. Ginzler, D. Wallace et al., “Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus,” *Arthritis & Rheumatism*, vol. 64, no. 10, pp. 3364–3373, 2012.

[9] C. Lass-Flörl and A. Mayr, “Human protothecosis,” *Clinical Microbiology Reviews*, vol. 20, no. 2, pp. 230–242, 2007.

[10] S. M. Kantrow and A. S. Boyd, “Protothecosis,” *Dermatologic Clinics*, vol. 21, no. 2, pp. 249–255, 2003.

[11] J. Mayorga, J. E. Barba-Gómez, A. P. Verduzco-Martínez, V. E. Muñoz-Estrada, and O. Welsh, “Protothecosis,” *Clinics in Dermatology*, vol. 30, no. 4, pp. 432–436, 2012.

### Table 1: Positive microbiology cultures during hospitalization.

| Date       | Source of culture | Organism                      |
|------------|-------------------|-------------------------------|
| 5/27/12    | Urine             | *Escherichia coli*            |
| 5/31/12    | Bronchoalveolar lavage | *Cytomegalovirus*          |
| 6/1/12     | Blood             | *Cytomegalovirus*            |
| 6/12/12    | Bronchoalveolar lavage | *Pneumocystis jiroveci*      |
| 7/3/12     | Bronchoalveolar lavage | *Herpes simplex virus*      |
| 7/9/12     | Blood             | *Cytomegalovirus*            |
| 7/15/12    | Urine             | Yeast, *Enterococcus species* |
| 7/15/12    | Blood             | *Enterococcus faecalis*      |
| 7/19/12    | Urine             | Yeast, *Enterococcus species* |
| 7/19/12    | Blood             | *Enterococcus faecalis*, *Klebsiella pneumonia* |
| 7/20/12    | Blood             | *Prototheca wickerhamii*, *Klebsiella pneumonia* |
[12] B. McMullan, K. Muthiah, D. Stark, L. Lee, and D. Marriott, “Prototheca wickerhamii mimicking yeast: a cautionary tale,” *Journal of Clinical Microbiology*, vol. 49, no. 8, pp. 3078–3081, 2011.

[13] J. R. Todd, J. W. King, A. Oberle et al., “Protothecosis: report of a case with 20-year follow-up, and review of previously published cases,” *Medical Mycology*, vol. 50, no. 7, pp. 673–689, 2012.

[14] J. P. Phair, J. E. Williams, and H. P. Bassaris, “Phagocytosis and algicidal activity of human polymorphonuclear neutrophils against Prototheca wickerhamii,” *Journal of Infectious Diseases*, vol. 144, no. 1, pp. 72–76, 1981.

[15] V. Nwanguma, K. Cleveland, and V. Baselski, “Fatal case of protothecosis in a hematopoietic stem cell transplant recipient after infliximab treatment for graft-versus-host disease,” *Journal of Clinical Microbiology*, vol. 49, no. 11, p. 4024, 2011.